Warfarin Drug Interactions Quiz
160 Questions
0 Views

Warfarin Drug Interactions Quiz

Created by
@CleanlyBoston

Questions and Answers

Which of the following drugs is known to enhance the effect of warfarin?

  • Cimetidine (correct)
  • Aluminum hydroxide
  • Phenobarbital
  • Rifampin
  • What effect do oral antibiotics have on warfarin levels?

  • Enhance the effect of clotting factors
  • Inhibit warfarin metabolism
  • Decrease vitamin K synthesis (correct)
  • Increase warfarin absorption
  • Which of the following substances would likely decrease the absorption of vitamin K?

  • Oral contraceptives
  • Liquid paraffin (correct)
  • NSAIDs
  • Aluminum hydroxide
  • Which of the following would NOT increase the effectiveness of warfarin?

    <p>Rifampin</p> Signup and view all the answers

    How do fibrinolytic drugs like t-PAs work in the body?

    <p>They activate plasminogen into plasmin.</p> Signup and view all the answers

    Which of the following is a potential consequence of taking NSAIDs while on warfarin?

    <p>Displacement of warfarin from plasma proteins</p> Signup and view all the answers

    What is the mechanism by which chloramphenicol affects warfarin levels?

    <p>It inhibits the metabolism of warfarin.</p> Signup and view all the answers

    Which of the following conditions must microsomal enzyme inducers like phenobarbital create for warfarin?

    <p>Increased warfarin metabolism.</p> Signup and view all the answers

    What is the primary function of recombinant tissue plasminogen activators (t-PAs)?

    <p>To activate plasminogen at the thrombus site</p> Signup and view all the answers

    Which of the following t-PAs allows for administration as a single intravenous injection?

    <p>Tenecteplase</p> Signup and view all the answers

    What is a significant advantage of using reteplase and tenecteplase over alteplase?

    <p>They can be administered as bolus injections</p> Signup and view all the answers

    In which scenario should thrombolytic drugs be administered within 12 hours?

    <p>In cases of acute myocardial infarction</p> Signup and view all the answers

    How are thrombolytic drugs typically administered?

    <p>Intravenously</p> Signup and view all the answers

    What effect does local activation of plasminogen by t-PAs have on bleeding risk?

    <p>Reduces the incidence of systemic bleeding</p> Signup and view all the answers

    Which of the following statements is true regarding the thrombolytic action of t-PAs?

    <p>They are fibrin-specific</p> Signup and view all the answers

    Which condition is NOT a typical therapeutic use for thrombolytic drugs?

    <p>Chronic obstructive pulmonary disease</p> Signup and view all the answers

    What is the primary function of plasmin in the body?

    <p>Lysis of the clot</p> Signup and view all the answers

    What is a significant drawback of fibrinolytic drugs?

    <p>They may cause systemic activation of plasminogen.</p> Signup and view all the answers

    Streptokinase and urokinase both activate plasminogen. How do they differ in their source?

    <p>Urokinase is isolated from urine and prepared in recombinant form; streptokinase is isolated from streptococci.</p> Signup and view all the answers

    Which statement about urokinase is true?

    <p>It is derived from cultured kidney cells.</p> Signup and view all the answers

    What potential risk is associated with the use of fibrinolytic drugs?

    <p>Increased risk of bleeding.</p> Signup and view all the answers

    What characteristic of streptokinase may pose a concern for some patients?

    <p>It may be antigenic and cause allergic reactions.</p> Signup and view all the answers

    How does plasminogen activation occur during fibrinolysis?

    <p>By both endogenous and exogenous activators.</p> Signup and view all the answers

    What is a key advantage of endogenous activators over fibrinolytic drugs?

    <p>They preferentially activate plasminogen bound to fibrin.</p> Signup and view all the answers

    What is the optimal time frame for administering treatment to obtain maximum benefit?

    <p>Within 90 minutes</p> Signup and view all the answers

    What is the primary adverse effect associated with thrombolytic drugs?

    <p>Systemic bleeding</p> Signup and view all the answers

    Which thrombolytic agent is associated with a higher risk of allergic reactions?

    <p>Streptokinase</p> Signup and view all the answers

    How does aspirin inhibit platelet aggregation?

    <p>By blocking TXA2 production</p> Signup and view all the answers

    What can be a critical site for assessing bleeding risk before thrombolysis?

    <p>Central nervous system</p> Signup and view all the answers

    What mechanism does aspirin use to cause irreversible inhibition in platelets?

    <p>Acetylation of platelet cell membranes</p> Signup and view all the answers

    Which thrombolytic agent has a lower associated risk of systemic bleeding?

    <p>Tissue plasminogen activator</p> Signup and view all the answers

    What effect does aspirin have on thromboxane A2 (TXA2) levels in platelets?

    <p>It decreases TXA2 levels</p> Signup and view all the answers

    Microsomal enzyme inducers increase the metabolism of warfarin.

    <p>True</p> Signup and view all the answers

    Chloramphenicol is a drug that decreases the effect of warfarin.

    <p>False</p> Signup and view all the answers

    Liquid paraffin enhances the absorption of vitamin K.

    <p>False</p> Signup and view all the answers

    Oral antibiotics can lead to increased synthesis of vitamin K.

    <p>False</p> Signup and view all the answers

    NSAIDs may displace warfarin from plasma proteins, enhancing its anticoagulant activity.

    <p>True</p> Signup and view all the answers

    Thrombolytic drugs activate plasminogen into plasmin in the presence of fibrin clots.

    <p>True</p> Signup and view all the answers

    Aluminum hydroxide is known to increase the absorption of warfarin.

    <p>False</p> Signup and view all the answers

    Vitamin K is critical for the activation of clotting factors.

    <p>True</p> Signup and view all the answers

    Recombinant tissue plasminogen activators (t-PAs) have a short half-life that requires continuous infusion for administration.

    <p>False</p> Signup and view all the answers

    T-PAs are primarily used for the treatment of acute myocardial infarction within 24 hours of onset.

    <p>False</p> Signup and view all the answers

    The local activation of plasminogen by t-PAs increases the risk of systemic bleeding.

    <p>False</p> Signup and view all the answers

    All therapeutic uses of thrombolytic drugs are limited to conditions involving ischemic strokes.

    <p>False</p> Signup and view all the answers

    Reteplase can be administered through two intravenous injections that are separated by a full hour.

    <p>False</p> Signup and view all the answers

    Tissue plasminogen activators are produced from cultured bacterial cells.

    <p>False</p> Signup and view all the answers

    Tenecteplase is administered as a single intravenous injection for the treatment of acute conditions.

    <p>True</p> Signup and view all the answers

    Plasmin is activated only at the systemic level during thrombolytic therapy.

    <p>False</p> Signup and view all the answers

    Treatment is most beneficial if given within 60 minutes of the onset of pain.

    <p>False</p> Signup and view all the answers

    Streptokinase has a higher risk of causing allergic reactions compared to other thrombolytic agents.

    <p>True</p> Signup and view all the answers

    Systemic bleeding is considered a minor adverse effect of thrombolytic drugs.

    <p>False</p> Signup and view all the answers

    Aspirin inhibits platelet aggregation by enhancing the production of TXA2.

    <p>False</p> Signup and view all the answers

    Thrombolytic drugs should be administered without concern for bleeding risks in critical sites.

    <p>False</p> Signup and view all the answers

    Aspirin causes reversible acetylation of platelet cell membranes, leading to decreased platelet adhesion.

    <p>False</p> Signup and view all the answers

    The risk of bleeding is low with streptokinase compared to recent recombinant tissue plasminogen activators.

    <p>False</p> Signup and view all the answers

    Thrombolytic drugs are always contraindicated in patients with a previous history of bleeding complications.

    <p>False</p> Signup and view all the answers

    Plasmin is responsible for lysis of the clot.

    <p>True</p> Signup and view all the answers

    Streptokinase is an enzyme that activates plasminogen enzymatically.

    <p>False</p> Signup and view all the answers

    Urokinase has a higher antigenic potential than streptokinase.

    <p>False</p> Signup and view all the answers

    Fibrinolytic drugs preferentially activate plasminogen bound to circulating proteins.

    <p>False</p> Signup and view all the answers

    The use of fibrinolytic drugs does not pose a risk of systemic bleeding.

    <p>False</p> Signup and view all the answers

    Plasminogen activation is solely dependent on endogenous activators in the body.

    <p>False</p> Signup and view all the answers

    Fibrinolysis is a process that aims to avoid systemic activation of plasminogen.

    <p>True</p> Signup and view all the answers

    Recombinant urokinase is derived from cultured kidney cells.

    <p>True</p> Signup and view all the answers

    What specific condition allows t-PAs to reduce the incidence of systemic bleeding during thrombolysis?

    <p>The local activation of plasminogen bound to fibrin at the thrombus site.</p> Signup and view all the answers

    Why are reteplase and tenecteplase favored over alteplase in some clinical scenarios?

    <p>They have longer half-lives, allowing for administration as a bolus instead of continuous infusion.</p> Signup and view all the answers

    In what time frame should thrombolytic therapy be initiated for acute myocardial infarction for optimal effectiveness?

    <p>Within 12 hours of onset.</p> Signup and view all the answers

    Describe the administration approach for reteplase in emergency situations.

    <p>It involves two intravenous injections separated by 30 minutes.</p> Signup and view all the answers

    What is the primary administration route for thrombolytic drugs when treating conditions like pulmonary embolism?

    <p>Intravenous route (i.v.).</p> Signup and view all the answers

    Explain the mechanism by which t-PAs achieve their therapeutic effect?

    <p>They activate plasminogen into plasmin specifically at thrombus sites bound to fibrin.</p> Signup and view all the answers

    What are the therapeutic indications for administering thrombolytic drugs?

    <p>Acute myocardial infarction, ischemic stroke, pulmonary embolism, and arterial thrombosis.</p> Signup and view all the answers

    What is a significant drawback of using alteplase compared to reteplase or tenecteplase?

    <p>Alteplase requires continuous infusion due to its shorter half-life.</p> Signup and view all the answers

    What is the primary role of plasmin in the clotting process?

    <p>Plasmin is responsible for the lysis of fibrin clots.</p> Signup and view all the answers

    How does streptokinase non-enzymatically activate plasminogen?

    <p>Streptokinase binds to plasminogen and triggers its conversion to plasmin without requiring enzymatic activity.</p> Signup and view all the answers

    In what way does urokinase differ from streptokinase in terms of immunogenicity?

    <p>Urokinase is less antigenic than streptokinase, reducing the likelihood of allergic reactions.</p> Signup and view all the answers

    Why is the systemic activation of plasminogen by fibrinolytic drugs concerning?

    <p>It poses a risk of bleeding by dissolving both protective hemostatic thrombi and pathogenic thromboemboli.</p> Signup and view all the answers

    What is the mechanism by which endogenous activators limit fibrinolysis to formed thrombi?

    <p>Endogenous activators preferentially activate plasminogen bound to fibrin, confining the process to the clot site.</p> Signup and view all the answers

    What are the implications of using fibrinolytic drugs in patients with existing thrombi?

    <p>Fibrinolytic drugs can inadvertently break down essential thrombi, increasing the risk of serious bleeding complications.</p> Signup and view all the answers

    Discuss the source and preparation method of urokinase.

    <p>Urokinase is originally isolated from urine and is now prepared in recombinant form from cultured kidney cells.</p> Signup and view all the answers

    Why might some patients experience allergic reactions to streptokinase?

    <p>Streptokinase can be antigenic, which means it may trigger an immune response in some individuals.</p> Signup and view all the answers

    What role do oral antibiotics play in the metabolism of warfarin?

    <p>Oral antibiotics decrease vitamin K synthesis by killing gut flora.</p> Signup and view all the answers

    How does liquid paraffin affect the absorption of vitamin K?

    <p>Liquid paraffin decreases the absorption of vitamin K.</p> Signup and view all the answers

    What is the effect of NSAIDs on warfarin levels in the bloodstream?

    <p>NSAIDs may displace warfarin from plasma proteins, enhancing its anticoagulant activity.</p> Signup and view all the answers

    What is the mechanism by which microsomal enzyme inducers affect warfarin?

    <p>Microsomal enzyme inducers, like phenobarbital, increase the metabolism of warfarin.</p> Signup and view all the answers

    How do fibrinolytic drugs like t-PAs activate plasminogen?

    <p>Fibrinolytic drugs activate plasminogen to plasmin in the presence of fibrin clots.</p> Signup and view all the answers

    What common effect do microsomal enzyme inhibitors have on warfarin levels?

    <p>Microsomal enzyme inhibitors decrease the metabolism of warfarin.</p> Signup and view all the answers

    Which substance can increase the synthesis of clotting factors while on warfarin?

    <p>Oral contraceptives increase the synthesis of clotting factors.</p> Signup and view all the answers

    What is a potential consequence of the use of aluminum hydroxide with warfarin?

    <p>Aluminum hydroxide can decrease the absorption of warfarin.</p> Signup and view all the answers

    What is the ideal time frame for administering thrombolytic treatment to achieve maximum benefit?

    <p>90 minutes after the onset of pain.</p> Signup and view all the answers

    What is the major adverse effect associated with systemic use of thrombolytic drugs?

    <p>Systemic bleeding.</p> Signup and view all the answers

    Which thrombolytic agent has a higher likelihood of inducing allergic reactions?

    <p>Streptokinase.</p> Signup and view all the answers

    How does aspirin affect platelet aggregation?

    <p>Aspirin irreversibly inhibits the COX enzyme, leading to decreased TXA2 and platelet aggregation.</p> Signup and view all the answers

    What precautions should be taken concerning critical sites before administering thrombolysis?

    <p>Ensure there is no risk of bleeding in critical sites such as the CNS or retina.</p> Signup and view all the answers

    What effect does the irreversible acetylation by aspirin have on platelets?

    <p>It decreases platelet adhesions.</p> Signup and view all the answers

    What are the two mechanisms by which aspirin inhibits platelet aggregation?

    <p>Irreversible inhibition of COX enzyme and irreversible acetylation of platelet cell membranes.</p> Signup and view all the answers

    What conditions are advised to be assessed for bleeding liability before thrombolytic therapy?

    <p>Critical sites such as CNS and retina.</p> Signup and view all the answers

    Drugs that potentiate warfarin include microsomal enzyme ______

    <p>inhibitors</p> Signup and view all the answers

    Oral antibiotics decrease vitamin K synthesis by killing the gut ______

    <p>flora</p> Signup and view all the answers

    Liquid paraffin results in decreased absorption of vitamin ______

    <p>K</p> Signup and view all the answers

    NSAIDs may ______ warfarin from plasma proteins, enhancing its anticoagulant activity.

    <p>displace</p> Signup and view all the answers

    Fibrinolytic drugs activate plasminogen into plasmin in the presence of ______ clots.

    <p>fibrin</p> Signup and view all the answers

    Aluminum hydroxide is known to decrease the absorption of ______.

    <p>warfarin</p> Signup and view all the answers

    Vitamin K is critical for the activation of clotting ______.

    <p>factors</p> Signup and view all the answers

    Tissue plasminogen activators (t-PAs) are produced from cultured ______ cells.

    <p>bacterial</p> Signup and view all the answers

    Recombinant tissue plasminogen activators (t-PAs) are produced in cultured ______.

    <p>cells</p> Signup and view all the answers

    Reteplase and tenecteplase have a long half-life which allows for ______ administration as a bolus.

    <p>iv</p> Signup and view all the answers

    Thrombolytic drugs are given by the ______ route in cases of acute myocardial infarction.

    <p>iv</p> Signup and view all the answers

    The local activation of plasminogen at the thrombus site reduces the incidence of ______ bleeding.

    <p>systemic</p> Signup and view all the answers

    Therapeutic uses of thrombolytic drugs include treatment for pulmonary ______ and arterial thrombosis.

    <p>embolism</p> Signup and view all the answers

    In acute myocardial infarction, thrombolytic drugs should be administered within ______ hours of onset.

    <p>12</p> Signup and view all the answers

    Alteplase, reteplase, and tenecteplase are examples of ______ tissue plasminogen activators.

    <p>recombinant</p> Signup and view all the answers

    Reteplase requires two intravenous injections separated by ______ minutes.

    <p>30</p> Signup and view all the answers

    Plasmin causes lysis of the ______.

    <p>clot</p> Signup and view all the answers

    Fibronolytic drugs cause rapid activation of plasminogen to form ______.

    <p>plasmin</p> Signup and view all the answers

    Streptokinase is a protein isolated from ______.

    <p>streptococci</p> Signup and view all the answers

    Urokinase is a protease originally isolated from ______.

    <p>urine</p> Signup and view all the answers

    Streptokinase activates plasminogen into plasmin ______.

    <p>non-enzymatically</p> Signup and view all the answers

    Urokinase is less ______ than streptokinase.

    <p>antigenic</p> Signup and view all the answers

    The activation of plasminogen is preferentially confined to the ______ thrombus.

    <p>formed</p> Signup and view all the answers

    Fibrinolytic drugs may break down protective hemostatic thrombi and pathogenic ______.

    <p>thromboemboli</p> Signup and view all the answers

    The maximum benefit is obtained if treatment is given within ______ minutes of the onset of pain.

    <p>90</p> Signup and view all the answers

    Systemic bleeding is the major adverse effect, with the risk being high with ______ and low with recombinant tissue plasminogen activators.

    <p>streptokinase</p> Signup and view all the answers

    Aspirin inhibits platelet aggregation by irreversible inhibition of the ______ enzyme.

    <p>COX</p> Signup and view all the answers

    Irreversible acetylation of platelet cell membranes leads to decreased platelet ______.

    <p>adhesions</p> Signup and view all the answers

    Streptokinase can cause allergy, fever, and ______ during i.v. infusion.

    <p>hypotension</p> Signup and view all the answers

    The major adverse effect of thrombolytic drugs is ______ in critical sites.

    <p>bleeding</p> Signup and view all the answers

    The risk of bleeding increases if thrombolytic therapy is not monitored for critical ______ sites.

    <p>liability</p> Signup and view all the answers

    Aspirin leads to decreased levels of ______ in platelets.

    <p>TXA2</p> Signup and view all the answers

    Match the following drugs with their effects on warfarin:

    <p>Cimetidine = Inhibits warfarin metabolism Aluminum hydroxide = Decreases warfarin absorption Phenobarbital = Increases warfarin metabolism Oral antibiotics = Decreases vitamin K synthesis</p> Signup and view all the answers

    Match the following drug classes with their interactions with warfarin:

    <p>NSAIDs = Displace warfarin from plasma proteins Liquid paraffin = Decreases vitamin K absorption Microsomal enzyme inducers = Increase metabolism of warfarin Oral contraceptives = Increase vitamin K synthesis</p> Signup and view all the answers

    Match the following conditions with the appropriate effects on warfarin:

    <p>Chloramphenicol = Decreases effect of warfarin Rifampin = Increases effect of warfarin Oral antibiotics = Decrease vitamin K levels Microsomal enzyme inhibitors = Increase warfarin levels</p> Signup and view all the answers

    Match the following agents with their effects on vitamin K:

    <p>Liquid paraffin = Reduces absorption of vitamin K Oral antibiotics = Reduces synthesis of vitamin K Cimetidine = Inhibits vitamin K metabolism Phenobarbital = Enhances vitamin K synthesis</p> Signup and view all the answers

    Match the following thrombolytic agents with their characteristics:

    <p>Reteplase = Administered as two intravenous injections Tenecteplase = Single intravenous injection Alteplase = Requires continuous infusion Streptokinase = Higher risk of allergic reactions</p> Signup and view all the answers

    Match the following statements with their context regarding plasminogen activation:

    <p>t-PAs = Activate plasminogen in the presence of fibrin Streptokinase = Activates plasminogen systemically Urokinase = Acts primarily in the bloodstream Endogenous activators = Activate plasminogen locally</p> Signup and view all the answers

    Match the following statements regarding vitamin K interactions:

    <p>Antibiotics = Decrease gut flora, affecting vitamin K Liquid paraffin = Affects vitamin K absorption NSAIDs = May enhance warfarin effects through displacement Phenobarbital = Accelerates warfarin metabolism</p> Signup and view all the answers

    Match the drugs with their respective effects on anticoagulant agents:

    <p>Chloramphenicol = Inhibits warfarin's effect Aluminum hydroxide = Decreases absorption of anticoagulants Oral contraceptives = Increase clotting factor synthesis Cimetidine = Inhibits anticoagulant metabolism</p> Signup and view all the answers

    Match the thrombolytic drugs with their associated risks or characteristics:

    <p>Streptokinase = Higher risk of allergy and fever Recombinant tissue plasminogen activators = Lower risk of systemic bleeding Alteplase = Requires continuous infusion Urokinase = Activated from human kidney cells</p> Signup and view all the answers

    Match the components of aspirin's mechanism to its effects on platelet aggregation:

    <p>Inhibition of COX enzyme = Decreased TXA2 production Reversible acetylation = Increased platelet adhesion Irreversible inhibition = Reduced platelet aggregation Increased TXA2 = Enhanced clot formation</p> Signup and view all the answers

    Match the adverse effects with the respective thrombolytic drugs:

    <p>Streptokinase = Causes hypotension during infusion Alteplase = Potential risk of bleeding complications Urokinase = Allergic reactions are rare Tenecteplase = Single injection administration</p> Signup and view all the answers

    Match the following terms with their descriptions:

    <p>Thrombolytic therapy = Treatment aimed at dissolving blood clots Fibrinolysis = The process of breaking down fibrin in clots Antiplatelet drugs = Inhibits platelet aggregation Thrombus = A blood clot formed within a blood vessel</p> Signup and view all the answers

    Match the adverse effects of thrombolytic therapy with their potential implications:

    <p>Systemic bleeding = Major concern with thrombolytic drugs Allergic reactions = More common with streptokinase Hypotension = Potential side effect of intravenous infusion Increased TXA2 = Risks clot formation and aggregation</p> Signup and view all the answers

    Match the thrombolytic drug with its primary mechanism of action:

    <p>Streptokinase = Activates plasminogen into plasmin Alteplase = Directly converts plasminogen to plasmin Urokinase = Catalyzes the conversion of plasminogen Tenecteplase = Modified form of alteplase for faster action</p> Signup and view all the answers

    Match the concept of maximal benefit timing with the respective time frame:

    <p>Thrombolysis = Within 90 minutes of symptom onset Aspirin administration = As soon as symptoms appear Fibrinolytic therapy = Within 12 hours for best results Antiplatelet therapy = Before thrombolytic therapy begins</p> Signup and view all the answers

    Match the type of bleeding risk with its critical site:

    <p>Central Nervous System = High bleeding risk with thrombolysis Gastrointestinal tract = Common site for potential bleeding Retroperitoneal space = Another critical site for hemorrhage Retina = Specific site that warrants caution before treatment</p> Signup and view all the answers

    Match the following recombinant tissue plasminogen activators (t-PAs) with their characteristics:

    <p>Alteplase = Short half-life requiring continuous infusion Reteplase = Administered in two intravenous injections Tenecteplase = Administered as a single intravenous injection None = Derived from animal sources</p> Signup and view all the answers

    Match the following thrombolytic conditions with their appropriate administration timing:

    <p>Acute myocardial infarction = Within 12 hours of onset Ischemic stroke = Within 24 hours of onset Pulmonary embolism = Administered any time before symptoms subside Arterial thrombosis = Within 6 hours of onset</p> Signup and view all the answers

    Match the following activating processes of t-PAs with their description:

    <p>Local activation of plasminogen = Decreases incidence of systemic bleeding Fibrin-bound plasminogen = Enhanced activation at the thrombus site Systemic activation of plasminogen = Increases risk of bleeding complications Short half-life of t-PAs = Requires long-term infusion</p> Signup and view all the answers

    Match the following therapeutic uses of thrombolytic drugs with their corresponding conditions:

    <p>Acute myocardial infarction = Treatment of heart attack Pulmonary embolism = Blocked blood vessel in the lungs Ischemic stroke = Loss of blood flow to the brain Arterial thrombosis = Clots in arteries leading to limb ischemia</p> Signup and view all the answers

    Match the following intravenous administration features of t-PAs with their effects:

    <p>Reteplase = Requires two injections, 30 minutes apart Tenecteplase = Single injection administration Alteplase = Continuous infusion necessary for effective treatment All t-PAs = Administered by oral route</p> Signup and view all the answers

    Match the following characteristics of recombinant human proteins with their details:

    <p>Produced in cultured cells = All t-PAs are synthesized this way Half-life comparisons = Reteplase and tenecteplase have longer half-lives Mechanism of action = Convert plasminogen to plasmin Side effects = All t-PAs have similar risk profiles</p> Signup and view all the answers

    Match the following aspects of thrombolytic therapy with their outcomes:

    <p>Local activation of plasminogen = Increases effectiveness at thrombus site Long half-life of drugs = Allows for less frequent dosing Administration within 12 hours = Optimizes patient outcomes All intravenous routes = Have the same efficacy and effectiveness</p> Signup and view all the answers

    Match the following t-PAs with their production sources:

    <p>Alteplase = Human recombinant protein Reteplase = Derived from cell cultures Tenecteplase = Not derived from bacteria All mentioned t-PAs = Produced from animal tissues</p> Signup and view all the answers

    Match the following thrombolytic agents with their source:

    <p>Streptokinase = Isolated from streptococci Urokinase = Originated from urine Recombinant t-PA = Produced from cultured bacterial cells Alteplase = Derived from tissue culture</p> Signup and view all the answers

    Match the following properties with the corresponding thrombolytic agent:

    <p>Streptokinase = May cause allergic reactions Urokinase = Less antigenic than streptokinase Plasmin = Causes lysis of fibrin clots Fibrinolytic drugs = Rapidly activate plasminogen</p> Signup and view all the answers

    Match the following statements with their corresponding effects:

    <p>Endogenous activators = Confine fibrinolysis to formed thrombus Fibrinolytic drugs = Activate both bound and circulating plasminogen Non-enzymatic activation = Occurs with streptokinase Antigenic response = Potential effect of streptokinase</p> Signup and view all the answers

    Match the following drugs with their activation mechanisms:

    <p>Streptokinase = Non-enzymatically activates plasminogen Urokinase = Activates plasminogen from kidney cells Fibrinolytic drugs = Rapidly convert plasminogen to plasmin Plasmin = Degrades fibrin and holds clot lysis</p> Signup and view all the answers

    Match the following definitions to their terms:

    <p>Fibrinolytic drugs = Cause breakdown of pathogenic thromboemboli Plasminogen = Inactive precursor to plasmin in fibrinolysis Thrombus = A formation that can be lysed by plasmin Hemostasis = Protective mechanism that can be disrupted by drugs</p> Signup and view all the answers

    Match the following properties of drugs with their comparison:

    <p>Streptokinase = Higher risk of allergic reactions Urokinase = Less risk of antigenicity Fibrinolytic agents = Activate plasminogen generally nonspecifically Endogenous activators = Minimize systemic activation risks</p> Signup and view all the answers

    Match the following risk factors to their descriptions:

    <p>Risk of bleeding = Associated with both fibrinolytic drugs and thrombolysis Systemic activation = Can occur when using fibrinolytic agents indiscriminately Antigenic reactions = Specifically a concern for streptokinase Local fibrinolysis = Operational function of t-PAs in therapy</p> Signup and view all the answers

    Match the following conditions with their effects on thrombolysis:

    <p>Fibrinolytic drugs = Increase risk of bleeding Endogenous activators = Focus fibrinolysis at the clot site Streptokinase = Potentially induces allergic reactions in some Urokinase = May induce less allergic response than streptokinase</p> Signup and view all the answers

    Study Notes

    Drug Interactions with Oral Anticoagulants (Warfarin)

    • Potentiating Drugs: Medications that increase warfarin's effects.

      • Microsomal Enzyme Inhibitors: Includes cimetidine and chloramphenicol, which decrease warfarin metabolism.
      • Oral Antibiotics: Reduce Vitamin K synthesis by killing gut flora, impacting clotting factor production.
      • Liquid Paraffin: Decreases Vitamin K absorption in the body.
      • NSAIDs: Displace warfarin from plasma protein binding, leading to increased anticoagulant effects.
    • Inhibiting Drugs: Medications that decrease warfarin's effects.

      • Microsomal Enzyme Inducers: Such as phenobarbital and rifampicin, which increase warfarin metabolism.
      • Oral Contraceptives and Vitamin K: Increase synthesis of clotting factors, counteracting warfarin.

    Fibrinolytic (Thrombolytic) Drugs

    • Mechanism of Action: Plasminogen is activated to plasmin, which lyses fibrin clots, predominantly in areas where thrombi are present to minimize systemic effects.
    • Risks: Fibrinolytic agents can activate circulating plasminogen as well, resulting in bleeding risks from both protective and pathologic thrombi.

    Key Fibrinolytic Agents

    • Streptokinase:

      • Protein isolated from streptococci, activates plasminogen non-enzymatically.
      • Can be antigenic, posing a risk for allergic reactions.
    • Urokinase:

      • Protease derived from urine, now primarily available in recombinant form.
      • Less antigenic compared to streptokinase.
    • Recombinant Tissue Plasminogen Activators (t-PAs):

      • Includes alteplase, reteplase, and tenecteplase, designed to act specifically on fibrin-bound plasminogen, reducing systemic bleeding risks.
      • Reteplase and tenecteplase have longer half-lives, allowing for less frequent dosing.

    Therapeutic Uses of Thrombolytic Drugs

    • Administered intravenously for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism, and arterial thrombosis.
    • Optimal efficacy if given within 90 minutes of the onset of symptoms, particularly for acute MI.
    • Precautions necessary to avoid bleeding risks, especially in critical areas like the CNS or retina.

    Adverse Effects of Thrombolytic Drugs

    • High risk of systemic bleeding, particularly with streptokinase.
    • Possible allergic reactions and transient side effects (fever, hypotension) during streptokinase administration.

    Antiplatelet Drugs

    • Aspirin:
      • Inhibits platelet aggregation through irreversible COX enzyme inhibition, reducing thromboxane A2 (TXA2) levels and subsequent platelet aggregation and adhesion.

    Drug Interactions with Oral Anticoagulants (Warfarin)

    • Potentiating Drugs: Medications that increase warfarin's effects.

      • Microsomal Enzyme Inhibitors: Includes cimetidine and chloramphenicol, which decrease warfarin metabolism.
      • Oral Antibiotics: Reduce Vitamin K synthesis by killing gut flora, impacting clotting factor production.
      • Liquid Paraffin: Decreases Vitamin K absorption in the body.
      • NSAIDs: Displace warfarin from plasma protein binding, leading to increased anticoagulant effects.
    • Inhibiting Drugs: Medications that decrease warfarin's effects.

      • Microsomal Enzyme Inducers: Such as phenobarbital and rifampicin, which increase warfarin metabolism.
      • Oral Contraceptives and Vitamin K: Increase synthesis of clotting factors, counteracting warfarin.

    Fibrinolytic (Thrombolytic) Drugs

    • Mechanism of Action: Plasminogen is activated to plasmin, which lyses fibrin clots, predominantly in areas where thrombi are present to minimize systemic effects.
    • Risks: Fibrinolytic agents can activate circulating plasminogen as well, resulting in bleeding risks from both protective and pathologic thrombi.

    Key Fibrinolytic Agents

    • Streptokinase:

      • Protein isolated from streptococci, activates plasminogen non-enzymatically.
      • Can be antigenic, posing a risk for allergic reactions.
    • Urokinase:

      • Protease derived from urine, now primarily available in recombinant form.
      • Less antigenic compared to streptokinase.
    • Recombinant Tissue Plasminogen Activators (t-PAs):

      • Includes alteplase, reteplase, and tenecteplase, designed to act specifically on fibrin-bound plasminogen, reducing systemic bleeding risks.
      • Reteplase and tenecteplase have longer half-lives, allowing for less frequent dosing.

    Therapeutic Uses of Thrombolytic Drugs

    • Administered intravenously for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism, and arterial thrombosis.
    • Optimal efficacy if given within 90 minutes of the onset of symptoms, particularly for acute MI.
    • Precautions necessary to avoid bleeding risks, especially in critical areas like the CNS or retina.

    Adverse Effects of Thrombolytic Drugs

    • High risk of systemic bleeding, particularly with streptokinase.
    • Possible allergic reactions and transient side effects (fever, hypotension) during streptokinase administration.

    Antiplatelet Drugs

    • Aspirin:
      • Inhibits platelet aggregation through irreversible COX enzyme inhibition, reducing thromboxane A2 (TXA2) levels and subsequent platelet aggregation and adhesion.

    Drug Interactions with Oral Anticoagulants (Warfarin)

    • Potentiating Drugs: Medications that increase warfarin's effects.

      • Microsomal Enzyme Inhibitors: Includes cimetidine and chloramphenicol, which decrease warfarin metabolism.
      • Oral Antibiotics: Reduce Vitamin K synthesis by killing gut flora, impacting clotting factor production.
      • Liquid Paraffin: Decreases Vitamin K absorption in the body.
      • NSAIDs: Displace warfarin from plasma protein binding, leading to increased anticoagulant effects.
    • Inhibiting Drugs: Medications that decrease warfarin's effects.

      • Microsomal Enzyme Inducers: Such as phenobarbital and rifampicin, which increase warfarin metabolism.
      • Oral Contraceptives and Vitamin K: Increase synthesis of clotting factors, counteracting warfarin.

    Fibrinolytic (Thrombolytic) Drugs

    • Mechanism of Action: Plasminogen is activated to plasmin, which lyses fibrin clots, predominantly in areas where thrombi are present to minimize systemic effects.
    • Risks: Fibrinolytic agents can activate circulating plasminogen as well, resulting in bleeding risks from both protective and pathologic thrombi.

    Key Fibrinolytic Agents

    • Streptokinase:

      • Protein isolated from streptococci, activates plasminogen non-enzymatically.
      • Can be antigenic, posing a risk for allergic reactions.
    • Urokinase:

      • Protease derived from urine, now primarily available in recombinant form.
      • Less antigenic compared to streptokinase.
    • Recombinant Tissue Plasminogen Activators (t-PAs):

      • Includes alteplase, reteplase, and tenecteplase, designed to act specifically on fibrin-bound plasminogen, reducing systemic bleeding risks.
      • Reteplase and tenecteplase have longer half-lives, allowing for less frequent dosing.

    Therapeutic Uses of Thrombolytic Drugs

    • Administered intravenously for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism, and arterial thrombosis.
    • Optimal efficacy if given within 90 minutes of the onset of symptoms, particularly for acute MI.
    • Precautions necessary to avoid bleeding risks, especially in critical areas like the CNS or retina.

    Adverse Effects of Thrombolytic Drugs

    • High risk of systemic bleeding, particularly with streptokinase.
    • Possible allergic reactions and transient side effects (fever, hypotension) during streptokinase administration.

    Antiplatelet Drugs

    • Aspirin:
      • Inhibits platelet aggregation through irreversible COX enzyme inhibition, reducing thromboxane A2 (TXA2) levels and subsequent platelet aggregation and adhesion.

    Drug Interactions with Oral Anticoagulants (Warfarin)

    • Potentiating Drugs: Medications that increase warfarin's effects.

      • Microsomal Enzyme Inhibitors: Includes cimetidine and chloramphenicol, which decrease warfarin metabolism.
      • Oral Antibiotics: Reduce Vitamin K synthesis by killing gut flora, impacting clotting factor production.
      • Liquid Paraffin: Decreases Vitamin K absorption in the body.
      • NSAIDs: Displace warfarin from plasma protein binding, leading to increased anticoagulant effects.
    • Inhibiting Drugs: Medications that decrease warfarin's effects.

      • Microsomal Enzyme Inducers: Such as phenobarbital and rifampicin, which increase warfarin metabolism.
      • Oral Contraceptives and Vitamin K: Increase synthesis of clotting factors, counteracting warfarin.

    Fibrinolytic (Thrombolytic) Drugs

    • Mechanism of Action: Plasminogen is activated to plasmin, which lyses fibrin clots, predominantly in areas where thrombi are present to minimize systemic effects.
    • Risks: Fibrinolytic agents can activate circulating plasminogen as well, resulting in bleeding risks from both protective and pathologic thrombi.

    Key Fibrinolytic Agents

    • Streptokinase:

      • Protein isolated from streptococci, activates plasminogen non-enzymatically.
      • Can be antigenic, posing a risk for allergic reactions.
    • Urokinase:

      • Protease derived from urine, now primarily available in recombinant form.
      • Less antigenic compared to streptokinase.
    • Recombinant Tissue Plasminogen Activators (t-PAs):

      • Includes alteplase, reteplase, and tenecteplase, designed to act specifically on fibrin-bound plasminogen, reducing systemic bleeding risks.
      • Reteplase and tenecteplase have longer half-lives, allowing for less frequent dosing.

    Therapeutic Uses of Thrombolytic Drugs

    • Administered intravenously for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism, and arterial thrombosis.
    • Optimal efficacy if given within 90 minutes of the onset of symptoms, particularly for acute MI.
    • Precautions necessary to avoid bleeding risks, especially in critical areas like the CNS or retina.

    Adverse Effects of Thrombolytic Drugs

    • High risk of systemic bleeding, particularly with streptokinase.
    • Possible allergic reactions and transient side effects (fever, hypotension) during streptokinase administration.

    Antiplatelet Drugs

    • Aspirin:
      • Inhibits platelet aggregation through irreversible COX enzyme inhibition, reducing thromboxane A2 (TXA2) levels and subsequent platelet aggregation and adhesion.

    Drug Interactions with Oral Anticoagulants (Warfarin)

    • Potentiating Drugs: Medications that increase warfarin's effects.

      • Microsomal Enzyme Inhibitors: Includes cimetidine and chloramphenicol, which decrease warfarin metabolism.
      • Oral Antibiotics: Reduce Vitamin K synthesis by killing gut flora, impacting clotting factor production.
      • Liquid Paraffin: Decreases Vitamin K absorption in the body.
      • NSAIDs: Displace warfarin from plasma protein binding, leading to increased anticoagulant effects.
    • Inhibiting Drugs: Medications that decrease warfarin's effects.

      • Microsomal Enzyme Inducers: Such as phenobarbital and rifampicin, which increase warfarin metabolism.
      • Oral Contraceptives and Vitamin K: Increase synthesis of clotting factors, counteracting warfarin.

    Fibrinolytic (Thrombolytic) Drugs

    • Mechanism of Action: Plasminogen is activated to plasmin, which lyses fibrin clots, predominantly in areas where thrombi are present to minimize systemic effects.
    • Risks: Fibrinolytic agents can activate circulating plasminogen as well, resulting in bleeding risks from both protective and pathologic thrombi.

    Key Fibrinolytic Agents

    • Streptokinase:

      • Protein isolated from streptococci, activates plasminogen non-enzymatically.
      • Can be antigenic, posing a risk for allergic reactions.
    • Urokinase:

      • Protease derived from urine, now primarily available in recombinant form.
      • Less antigenic compared to streptokinase.
    • Recombinant Tissue Plasminogen Activators (t-PAs):

      • Includes alteplase, reteplase, and tenecteplase, designed to act specifically on fibrin-bound plasminogen, reducing systemic bleeding risks.
      • Reteplase and tenecteplase have longer half-lives, allowing for less frequent dosing.

    Therapeutic Uses of Thrombolytic Drugs

    • Administered intravenously for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism, and arterial thrombosis.
    • Optimal efficacy if given within 90 minutes of the onset of symptoms, particularly for acute MI.
    • Precautions necessary to avoid bleeding risks, especially in critical areas like the CNS or retina.

    Adverse Effects of Thrombolytic Drugs

    • High risk of systemic bleeding, particularly with streptokinase.
    • Possible allergic reactions and transient side effects (fever, hypotension) during streptokinase administration.

    Antiplatelet Drugs

    • Aspirin:
      • Inhibits platelet aggregation through irreversible COX enzyme inhibition, reducing thromboxane A2 (TXA2) levels and subsequent platelet aggregation and adhesion.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    Test your knowledge on the various drug interactions that affect warfarin, including drugs that potentiate or inhibit its effects. This quiz covers important concepts related to microsomal enzyme inhibitors and their implications in anticoagulant therapy.

    More Quizzes Like This

    Use Quizgecko on...
    Browser
    Browser